53,000 Shares in Ionis Pharmaceuticals, Inc. $IONS Purchased by Carmignac Gestion

Carmignac Gestion purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the first quarter, according to its most recent disclosure with the SEC. The firm purchased 53,000 shares of the company’s stock, valued at approximately $3,980,000.

Several other institutional investors also recently bought and sold shares of the company. Brown Brothers Harriman & Co. purchased a new stake in Ionis Pharmaceuticals during the 4th quarter worth approximately $27,000. Cassaday & Co Wealth Management LLC acquired a new position in shares of Ionis Pharmaceuticals during the first quarter valued at approximately $30,000. Quarry LP acquired a new position in shares of Ionis Pharmaceuticals during the third quarter valued at approximately $38,000. Johnson Financial Group Inc. purchased a new position in shares of Ionis Pharmaceuticals in the third quarter valued at approximately $44,000. Finally, Laurel Wealth Advisors LLC purchased a new position in shares of Ionis Pharmaceuticals in the fourth quarter valued at approximately $47,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Michael R. Hayden bought 15,000 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was bought at an average cost of $53.38 per share, for a total transaction of $800,700.00. Following the acquisition, the director directly owned 19,000 shares in the company, valued at $1,014,220. This represents a 375.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Holly B. Kordasiewicz sold 60,846 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $73.41, for a total value of $4,466,704.86. Following the completion of the sale, the executive vice president directly owned 22,458 shares of the company’s stock, valued at $1,648,641.78. This trade represents a 73.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 233,163 shares of company stock valued at $18,316,551 in the last 90 days. 1.81% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on IONS shares. Wall Street Zen cut Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Wells Fargo & Company decreased their price objective on Ionis Pharmaceuticals from $100.00 to $95.00 and set an “overweight” rating on the stock in a report on Thursday. Guggenheim lowered their target price on shares of Ionis Pharmaceuticals from $106.00 to $89.00 and set a “buy” rating on the stock in a research note on Tuesday, July 21st. Bank of America upped their target price on shares of Ionis Pharmaceuticals from $100.00 to $111.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $69.00 target price on shares of Ionis Pharmaceuticals in a research report on Wednesday. Eighteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $94.85.

Key Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Ionis beat Wall Street’s second-quarter revenue and earnings expectations, helped by commercial growth despite difficult year-over-year comparisons. Management also reaffirmed its 2026 outlook, supporting confidence in the company’s operating trajectory. Zacks Q2 earnings report
• Positive Sentiment: Director Michael R. Hayden bought 15,000 shares for approximately $800,700 on July 30 and another 5,000 shares for $258,000 on July 31. The purchases materially increased his ownership and may be viewed as a signal of confidence in Ionis’s valuation and prospects. SEC insider-trading filing
• Neutral Sentiment: Wells Fargo lowered its price target from $100 to $95 while maintaining an “overweight” rating. The reduced target reflects more cautious valuation expectations, but the rating remains bullish. Benzinga analyst report
• Neutral Sentiment: HC Wainwright cut its target from $125 to $115 but retained a “buy” rating, similarly indicating lower near-term valuation expectations while maintaining a positive view of the stock. StreetInsider analyst report
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Ionis investors. Although the announcement does not establish wrongdoing, it adds legal and reputational uncertainty and may weigh on sentiment. Pomerantz investor alert

Ionis Pharmaceuticals Price Performance

IONS stock opened at $51.77 on Monday. The company has a debt-to-equity ratio of 3.07, a current ratio of 7.89 and a quick ratio of 7.73. The business has a 50 day simple moving average of $69.55 and a 200-day simple moving average of $74.52. The firm has a market capitalization of $8.60 billion, a PE ratio of -14.96 and a beta of 0.41. Ionis Pharmaceuticals, Inc. has a 1 year low of $40.03 and a 1 year high of $86.74.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.